Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2021

Filing Date
Filed February 15, 2022
Period End
December 31, 2021
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’16Dec ’16
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Mar ’21Mar ’21
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-K filed February 15, 2022. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (NASDAQ: MEDP) describes itself as one of the world's leading clinical contract research organizations by revenue, solely focused on outsourced clinical development services for the biotechnology, pharmaceutical and medical device industries, with particular strength in Oncology, Metabolic Disease, Cardiology, AVAI and CNS.

For 2021, net revenue rose to $1,142.4 milliona from $925.9 million in 2020, an increase of 23.4%, driven primarily by Oncology, Metabolic, Central Nervous System and other therapeutic areas. Income from operations was $198.6 million versus $167.0 million, and net income was $181.8 million, or $4.81 per diluted share, compared with $145.4 million and $3.84 per diluted share in 2020. The effective tax rate fell to 9.9% from 13.7%, mainly due to higher excess tax benefits from share-based compensation and FDII benefits.

Backlog ended 2021 at $1,997.1 millionb, up 29.5% from $1,541.7 million, and net new business awards were $1,610.4 million versus $1,175.0 million in 2020. The company expects approximately $1,030 million to $1,050 million of year-end backlog to convert to net revenue in 2022. Operating cash flow was $263.3 million, capital expenditures were $28.3 million, and cash and cash equivalents were $461.3 million at year-end, with no borrowings outstanding under its $50.0 million Credit Facility.

The company repurchased $62.1 millionc of stock in 2021, and in February 2022 its board approved an additional $300 million repurchase authorization. The filing highlights risks including contract termination on short notice, backlog conversion, fixed-fee contract cost overruns, COVID-19 disruption, customer concentration among small and mid-sized biopharmaceutical companies (77% and 16% of 2021 net revenue, respectively), and founder and CEO August J.

Troendle's control of approximately 17.2%d of outstanding shares. Management reported effective internal control over financial reporting as of December 31, 2021.

Key Highlights

  1. Net revenue grew 23.4% to $1,142.4 million in 2021 from $925.9 million in 2020, broad-based with Oncology, Metabolic and CNS as primary drivers.
  2. Net income rose to $181.8 million ($4.81 diluted EPS) from $145.4 million ($3.84 diluted EPS), with the effective tax rate falling to 9.9% from 13.7%.
  3. Backlog increased 29.5% to $1,997.1 million at December 31, 2021; net new business awards totaled $1,610.4 million versus $1,175.0 million in 2020.
  4. Approximately $1,030 million to $1,050 million of year-end backlog is expected to convert to net revenue in 2022.
  5. Cash and cash equivalents were $461.3 million, operating cash flow was $263.3 million, and the company had no borrowings under its $50.0 million Credit Facility.
  6. Share repurchases totaled $62.1 million in 2021, and the board approved an additional $300 million repurchase authorization on February 10, 2022.
  7. Small biopharmaceutical customers accounted for 77% of 2021 net revenue and mid-sized customers for 16%; the CEO and founder controls approximately 17.2% of outstanding shares.

Financial Statements

FY2021 against FY2020

Line itemFY2021FY2020Change
Revenue$1.14B$925.92M+23.4%
SG&A Expenses$108.42M$92.16M+17.6%
Operating Expenses$943.76M$758.88M+24.4%
Operating Income$198.62M$167.04M+18.9%
Net Income$181.85M$145.38M+25.1%
EPS (Basic)$5.06$4.07+24.3%
EPS (Diluted)$4.81$3.84+25.3%
Shares Outstanding (Basic)35.86M35.63M+0.6%
Shares Outstanding (Diluted)37.70M37.71M0.0%

Frequently Asked Questions

  1. How did Medpace's revenue and profitability change in 2021?

    Net revenue increased $216.5 million, or 23.4%, to $1,142.4 million. Income from operations rose to $198.6 million from $167.0 million, and net income increased to $181.8 million from $145.4 million. The lower effective tax rate of 9.9%, versus 13.7% in 2020, was mainly due to higher excess tax benefits from share-based compensation and FDII benefits.

  2. What does the backlog indicate about future revenue?

    Backlog rose 29.5% to $1,997.1 million at December 31, 2021. The company expects approximately $1,030 million to $1,050 million to convert to net revenue in 2022. The filing cautions that backlog is not necessarily a reliable predictor of future results because contracts are generally terminable without cause on about 30 days' notice.

  3. What are the main risks for investors?

    Key risks include customer contract cancellations and delays, fixed-fee contracts that can lead to cost overruns, dependence on small and mid-sized biopharmaceutical customers, COVID-19 disruption to clinical sites, and international operations. Liability from clinical trials, cybersecurity and HIPAA/GDPR compliance are also highlighted. The filing notes that founder and CEO August J. Troendle controls approximately 17.2% of outstanding shares.

  4. How is Medpace funding its operations and returning capital to shareholders?

    Operations are funded mainly by operating cash flow, which was $263.3 million in 2021. Cash and cash equivalents were $461.3 million at year-end. The company had $49.8 million available under its Credit Facility and no outstanding borrowings. It repurchased $62.1 million of stock in 2021, has not paid dividends, and the board approved an additional $300 million repurchase authorization in February 2022.